BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 22, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Aug. 5, 2020

View Archived Issues
Handshake dollar sign

Teladoc, Livongo to merge after striking $18.5B deal

Following Siemens Healthineers AG’s announcement that it was picking up Varian Medical Systems Inc. for $16.4 billion, another multibillion-dollar deal has emerged. This time, Teladoc Health Inc. and Livongo Health Inc. have inked a definitive merger agreement with a value of $18.5 billion. The transaction is expected to close by the end of the fourth quarter, subject to shareholder approvals and other customary closing conditions. Read More
Product image

Eyenuk gets FDA nod for AI-based diabetic retinopathy screening tool

People with diabetes are at risk of developing diabetic retinopathy (DR), an eye condition that can cause vision loss and blindness. However, early detection and treatment can slow its progress. To that end, the Food and Drug Administration has cleared the way for Eyenuk Inc. to market its Eyeart autonomous artificial intelligence (AI) system for DR screening in the U.S. Read More
Regulatory-US-FDA-HQ.png

Saliva-based tests for COVID-19 continue to perplex FDA, test developers

Developers of tests for the SARS-CoV-2 virus have gained a tremendous amount of experience in a very small amount of time, and of all the media for sampling, saliva offers the easiest route for test administration. The U.S. FDA’s Tim Stenzel said on the Aug. 5 testing town hall, however, that the FDA and developers have discovered that this is an extremely difficult medium to work with. Read More
Isabelle Adenot

Eyeing faster reimbursement, France is optimizing evaluation process for med tech

PARIS – France’s Medical Device and Health Technology Evaluation Committee (CNEDiMTS), has published it latest annual activity report. This committee of the French National Authority for Health (HAS) evaluates medical devices with a view to their coverage by L’Assurance Maladie, the body which manages health care in France. Read More
Physician with patient

Saykara mobile AI assistant improves practice productivity 500%

Saykara Inc.’s artificial intelligence (AI) assistant enabled the Midwest Institute for Minimally Invasive Therapies (MIMIT Health) to boost practice productivity five-fold. The voice-enabled iOS-based app, named Kara, drafts visit summaries, updates the electronic health record, produces prescriptions, and more with limited involvement from clinicians. Read More

Appointments and advancements for Aug. 5, 2020

New hires and promotions in the med-tech industry, including: Corvent Medical. Read More

Financings for Aug. 5, 2020

Med-tech firms raising money in public or private financings, including: Emergent Biosolutions, Medx Health, Veracyte. Read More

In the clinic for Aug. 5, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Veracyte. Read More

Other news to note for Aug. 5, 2020

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aura Smart Air, Axim, Back 2 Basics Direct, BehaVR, Biotechnologies, Brainworks, Entrepix Medical, Eurofins, Fujirebio Diagnostics, H.U. Group Holdings, Iremedy, Medtronic, MeMD, Merchavia Holdings and Investments, Mevion Medical Systems, Orbbö Surgical, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Targetcancer Foundation, Tecan Group, Thermo Fisher Scientific, Trendlines Group, Withmydoc, W.L. Gore, Viacyte, Wishbone Medical, Zenzium. Read More

Regulatory actions for Aug. 5, 2020

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Endologix, Eyenuk, Life Spine, Neumodx, Roche, Sentinel Diagnostics, Siemens Healthineers. Read More

Regulatory front for Aug. 5, 2020

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Advamed, CME America, MDMA. Read More

BioWorld MedTech’s Orthopedics Extra for Aug. 5, 2020

Keeping you up to date on recent developments in orthopedics, including: Implanted neural stem cell grafts show functionality in spinal cord injuries; Silk scaffolds and magnetism to generate bone tissue and be able to use it in implants; Hydrogel paves way for biomedical breakthrough; New strategy against osteoporosis. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 21, 2026.
  • Acid alpha-glucosidase molecular structure isolated on black

    ‘Detargeted’ targeted gene therapy improves activity in Pompe

    BioWorld
    A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Microscopic view of the ebola virus

    WHO declares Ebola outbreak a public health emergency of international concern

    BioWorld
    The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
  • Nxera Pharma prepares and tests new GPR17 antagonists

    BioWorld Science
    Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing